Colorectal Cancer (CRC) is the third most common cancer worldwide1. Metastatic disease accounts for 40-50% of newly diagnosed patients and is associated with high morbidity1,2. Despite recent therapeutic advances, the prognosis for metastatic CRC (mCRC) remains poor. Early diagnosis and assignment of the most appropriate therapy pathway is therefore crucial. The KRAS/BRAF/PIK3CA Array from Randox allows the clinician to select appropriate patients for anti-EGFR therapy, maximising drug efficacy and minimising adverse side effects to the patient.
Vitamin B12 is found in many immunoassay controls. However, it is normally present at high, clinically insignificant levels, unsuitable when assessing assay sensitivity and performance at the clinical decision level. The Randox Acusera range of immunoassay controls provides clinically relevant levels capable of accurately assessing the sensitivity of vitamin B12 assays.